Health-Related Quality-of-Life and Health-Care Resource Utilization Assessment in Nabi-4514 and Nabi-4515 Phase 3 Studies.
Latest Information Update: 08 Aug 2023
Price :
$35 *
At a glance
- Drugs Nicotine abuse vaccine (Primary)
- Indications Smoking withdrawal
- Focus Therapeutic Use
- Sponsors Nabi Biopharmaceuticals
- 16 May 2012 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 09 Nov 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 28 Aug 2010 New trial record